Details for Patent: 11,896,562
✉ Email this page to a colleague
Which drugs does patent 11,896,562 protect, and when does it expire?
Patent 11,896,562 protects EVEKEO ODT and is included in one NDA.
Drugs Protected by US Patent 11,896,562
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | EVEKEO ODT | amphetamine sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 209905-001 | Jan 30, 2019 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS | ⤷ Subscribe | ||||
| Azurity | EVEKEO ODT | amphetamine sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 209905-002 | Jan 30, 2019 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS | ⤷ Subscribe | ||||
| Azurity | EVEKEO ODT | amphetamine sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 209905-003 | Jan 30, 2019 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS | ⤷ Subscribe | ||||
| Azurity | EVEKEO ODT | amphetamine sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 209905-004 | Jan 30, 2019 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
